| Therapeutic | Urelumab |
| Target | TNFRSF9 |
| Heavy Chain | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS |
| Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK |
| 100% seqID Fv Structure | 6mhr [Fvs: AB, DE] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 6mhr [Fvs: AB, DE] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G4 |
| Highest Clinical Trial (June '19) | Phase-II |
| Estimated Status (June '19) | Active |
| Recorded Developmental Technology | Medarex UltiMAb Mouse |
| INN Year Proposed | 2010 |
| INN Year Recommended | 2011 |
| Companies Involved | Bristol-Myers Squibb, National Cancer Institute (USA), Ono Pharmaceutical, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Chicago, Medarex |
| Conditions Approved | na |
| Conditions Active | Non-Hodgkin's lymphoma, Solid tumours, Glioblastoma, Multiple myeloma |
| Conditions Discontinued | Colorectal cancer, Head and neck cancer, Malignant melanoma, Non-small cell lung cancer |
| Notes | Jain paper: "VL sequence modified at one position to match patent document (US7659384) and JK germline" |
